From bench to bedside: Stem cell applications in gastric cancer therapy and their emerging clinical relevance

doi:10.4251/wjgo.v18.i3.115835

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 3

This Article

(35)

(34)

(0)

(454)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Mar 15, 2026; 18(3): 115835
Published online Mar 15, 2026. doi: 10.4251/wjgo.v18.i3.115835

Table 3 Therapy resistance mediated by gastric cancer stem cells gene-level insights

Gene/marker	Contribution to therapy resistance
CD133, CD44	Enriched after chemotherapy (cisplatin/oxaliplatin); mediate chemoresistance and tumor regrowth
GPX4, OTUD5, POLQ, DHODH	Protect GCSCs from ferroptosis; therapeutic vulnerability for drug development
PD-L1	Enhances immune evasion and CSC survival; predicts poor response to immunotherapy
TAP1 (low expression)	Impairs antigen presentation, promoting immune escape
AQP5, beclin-1, ULK1	Autophagy regulators that sustain stemness under stress and confer resistance
CYB5R1	Links redox balance to stemness and chemoresistance; high expression predicts poor survival

CD: Cluster of differentiation; DHODH: Dihydroorotate dehydrogenase; PD-L1: Programmed death-ligand 1; GCSC: Gastric cancer stem cell; CSC: Cancer stem cell.

Full Size Table

Citation: Prisacariu IA, Koumarelas KE, Papadopoulos P, Schizas D, Christodoulidis G. From bench to bedside: Stem cell applications in gastric cancer therapy and their emerging clinical relevance. World J Gastrointest Oncol 2026; 18(3): 115835
URL: https://www.wjgnet.com/1948-5204/full/v18/i3/115835.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i3.115835

Prisacariu IA, Koumarelas KE, Papadopoulos P, Schizas D, Christodoulidis G. From bench to bedside: Stem cell applications in gastric cancer therapy and their emerging clinical relevance. World J Gastrointest Oncol 2026; 18(3): 115835 [DOI: 10.4251/wjgo.v18.i3.115835]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.